NRG-BN010

A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

Principal Investigator

Stephen Bagley

Status

Disease Site

Brain [BN] Other

Phase

II

Developmental Therapeutics

Yes

Primary Objective

Safety Run-In: To determine the maximum-tolerated dose (MTD) among three sequential dose levels: single-agent tocilizumab 4mg/kg, single-agent tocilizumab 8mg/kg, and tocilizumab 8mg/kg + atezolizumab 1680mg (each administered with FSRT), to be used for subsequent phase II testing

Phase II (non-surgical cohort):To determine the efficacy of the combination of tocilizumab (anti-IL6R), atezolizumab (anti-PD-L1), and FSRT in recurrent GBM, as measured by the objective radiographic response rate (ORR)

Patient Population

Glioblastoma that is in first recurrence following prior first-line radiation therapy 

Target Accrual

53